Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com
Predictive Model Forecasts Advanced NSCLC Outcomes

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com
FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi
Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com
Legal Navigation Services Key to Addressing Disparities in Cancer Care

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com
Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
August 15th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 15th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Red FDA approval stamp | Image credit: chrisdorney - stock.adobe.com
April 5th 2024

Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors

Mary Caffrey Laura Joszt, MA
FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Will Shapiro, vice president of data science, Flatiron Health
April 5th 2024

Will Shapiro Discusses Ethical Challenges Across Various Artificial Intelligence Models in Oncology

Hayden E. Klein Pearl Steinzor
Will Shapiro, vice president of data science at Flatiron Health, explains the different ethical challenges associated with various forms of artificial intelligence models used in oncology care.
Jonathan E. Levitt, Esq, Frier Levitt, LLC
April 5th 2024

Jon Levitt Highlights Urgency for Stronger Employer Oversight of PBMs

Maggie L. Shaw Mary Caffrey
Jonathan E. Levitt, Esq, founding partner of boutique health care law firm Frier Levitt, LLC, discusses a recent class-action lawsuit brought against Johnson & Johnson in which an employee alleged a breach of fiduciary duty regarding her employer-sponsored pharmacy benefits.
AJMC
April 5th 2024

Trends in Low-Value Cancer Care During the COVID-19 Pandemic

Ravi B. Parikh, MD, MPP Yasin Civelek, PhD, MS Pelin Ozluk, PhD David Debono, MD Michael J. Fisch, MD, MPH Gosia Sylwestrzak, MA Justin E. Bekelman, MD Aaron L. Schwartz, MD, PhD
Among adults with newly diagnosed cancer, rates of low-value cancer services persisted throughout the COVID-19 pandemic in areas ranging from peridiagnosis imaging to end-of-life care.
Judy Alberto, MHA, RPh, BCOP, Community Oncology Alliance
April 5th 2024

Optimizing Formulary Management: COA's Judy Alberto Shares Insights

Maggie L. Shaw
Judy Alberto, MHA, RPh, BCOP, director of clinical initiatives at the Community Oncology Alliance (COA), addresses the challenges pharmacies face in managing formularies to provide optimal patient care.
COA 2024 | Image credit: COA
April 4th 2024

Navigating the Community Oncology Relationship With the Local Hospital

Mary Caffrey
A lawsuit that followed a health system revoking community oncologists' hospital privileges was the jumping off point for a discussion of how to manage this key relationship.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
April 4th 2024

Dr Mila Felder Discusses Peer-to-Peer Support in Health Care Organizations

Hayden E. Klein Pearl Steinzor
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, discusses the impact of peer support groups within a health care organization and its patients.
Emily Touloukian, DO, Coastal Cancer Center
April 1st 2024

2024 COA Community Oncology Conference Preview With Dr Emily Touloukian

Maggie L. Shaw
With the 2024 Community Oncology Conference, from the Community Oncology Alliance (COA), set to kick off this week in Orlando, Florida, The American Journal of Managed Care® spoke with Emily Touloukian, DO, COA board member and 1 of 6 cochairs for this year’s meeting, on highlights from the packed agenda and the power of advocacy.
Will Shapiro
March 28th 2024

Will Shapiro Discusses the Impact of Large Language Models on Cancer Care

Hayden E. Klein Pearl Steinzor
Will Shapiro, vice president of data science at Flatiron Health, discusses opportunities to implement artificial intelligence in cancer care.
Physician holds hand of patient | C Davids/peopleimages.com - stock.adobe.com
March 28th 2024

Oncologists Find Ethical Challenges With Artificial Intelligence in Cancer Care

Pearl Steinzor
Explainability, consent, and responsibility are noted as challenges that may hinder implementation of artificial intelligence (AI) in cancer care, according to a new study.
Woman with magnifying glass showing mole and birthmark on her body for prevention of melanoma | Peakstock - stock.adobe.com
March 19th 2024

Skin Cancer Incidence Highest Among Rural, SOC Individuals

Pearl Steinzor
Posters presented at the American Academy of Dermatology 2024 Annual Meeting identified significant health disparities among patients living in rural areas and those with skin of color (SOC).
FDA approved| Image credit: wladimir1804 - stock.adobe.com
March 15th 2024

FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy

Kristi Rosa
The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Help support advice guidance signpost | Image Credit: PX Media - stock.adobe.com
March 12th 2024

Navigating the Mental Health Challenges of Cancer Diagnosis, Treatment, and Survivorship

Maggie L. Shaw
Stress has potential links to worse outcomes in cancer, such as decreased quality of life and greater risks of disease progression and metastasis. There is a complex mix of emotions patients with cancer experience.
Breast cancer with lymphatics - Axel Kock - stock.adobe.com.jpeg
March 5th 2024

Annual Breast Cancer Screening Should Begin at Age 40 Years, Study Finds

Pearl Steinzor
Modeling estimates indicate that annual breast cancer screening starting at age 40 years provides the greatest benefit to women and reduces risk per examination.
Doctor comforting a patient | Image credit: lenetsnikolai - stock.adobe.com
March 1st 2024

Treating the Whole Person in Cancer Care: Addressing Comprehensive Services

Mary Caffrey
The session at ACCC's 50th Annual Meeting & Cancer Center Business Summit featured discussions on patient navigation, addressing patients' sexual health, needs of LGBTQ+ patients, and more.
Mila Felder, MD, FACEP
March 1st 2024

Dr Mila Felder Explains Advocate Health's Approach to Well-Being for the Postpandemic Oncology Workforce

Hayden E. Klein
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, talks about tailoring the Stanford Model of Professional Fulfillment to support the postpandemic oncology workforce.
Cost Sharing for Oral Lenvatinib Among Commercially Insured Patients
March 1st 2024

Cost Sharing for Oral Lenvatinib Among Commercially Insured Patients

Margaret I. Liang, MD, MS Ling Chen, MD, MPH Emeline M. Aviki, MD, MBA Jason D. Wright, MD
Among a cohort of insured patients with cancer, the median total monthly cost of oral lenvatinib was $17,253, and 75% of patients paid $100 or less out of pocket per month for the drug.
New ONCare Alliance logo | Image Credit: ONCare Alliance
February 29th 2024

QCCA, NCCA Merge to Form ONCare Among Independent Oncology Practices

Mary Caffrey
ONCare Alliance will be led by 2 of the leading women in community oncology, cochairs Barbara McAneny, MD, of the New Mexico Cancer Center, and Sibel Blau, MD, of Northwest Medical Specialties, PLLC, of Puyallup, Washington.
ACCC logo | Image credit: ACCC
February 29th 2024

What Are the Steps to Quality Improvement in Cancer Care?

Mary Caffrey
Quality Improvement (QI) projects require a series of distinct steps and timely data collection that will allow clinics to see if changes are yielding results, a consultant told attendees at a preconference workshop at ACCC.
what we're reading logo
February 26th 2024

What We’re Reading: Alabama IVF Ruling Impacts; Administrative Task Fees; Nursing Shortage Response

AJMC Staff
Patients with cancer express shock and anxiety over the recent ruling by the Alabama Supreme Court regarding frozen embryos; doctors are beginning to charge fees for administrative tasks; some universities are implementing accelerated nursing programs to help with the shortage.
Blue folder with Cancer diagnosis | vchalup - stock.adobe.com
February 22nd 2024

COVID-19 Pandemic's Disruption on Cancer Detection in the US

Pearl Steinzor
A nationwide analysis reveals a significant drop in cancer diagnoses, highlighting an urgent need for a catch-up in screening efforts.
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
February 16th 2024

Kiana Mehring Discusses the Future of Value-Based Oncology Care

Pearl Steinzor
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute, shares her thoughts on future directions in value-based oncology care and research.
Breast cancer - Axel Kock - stock.adobe.com.jpeg
February 14th 2024

Breast Cancer Incidence Highest Among Young Black Women in the US

Pearl Steinzor
Researchers have identified a surge in breast cancer rates among young women and racial disparities across age groups.
AJMC EBO logo | Image credit : AJMC
February 14th 2024

How Real-World Evidence Can Spur Collaboration and Changes in Oncology

Zhaohui Su, PhD
Chandler Cortina, MD, MS, FSSO, FACS | Image Credit: Froedtert & Medical College of Wisconsin
February 9th 2024

Getting to Know Dr Chandler Cortina, Breast Surgical Oncologist

Maggie L. Shaw
Chandler Cortina, MD, MS, FSSO, FACS, is assistant professor of surgery and breast surgical oncologist at Froedtert & the Medical College of Wisconsin. His current research focuses on breast cancer risk not only in general but also among transgender and gender-diverse populations.
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
February 7th 2024

COA's Dr Miriam Atkins: PBMs, HR 5526, and Marketplace Strategy

Maggie L. Shaw Pearl Steinzor
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance, discusses the impact of pharmacy benefit managers (PBMs) on health care costs and offers potential ways to remedy certain CMS decisions that negatively affect oncologists and their patients.
Blood sample test with positive diagnosis of thrombosis risk in a coagulation test | angellodeco - stock.adobe.com
February 2nd 2024

Risk of Venous Thromboembolism Increases After Cancer Surgery, Study Finds

Pearl Steinzor
The increased risk is likely due to the underlying cancer disease and adjuvant treatments, researchers find.
Enhertu (trastuzumab deruxtecan) product packaging | AstraZeneca photo
January 30th 2024

Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC

Mary Caffrey
A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.
Dr Lucy Langer
January 28th 2024

Dr Lucy Langer: How UnitedHealthcare Is Enhancing Oncology Pathway Adherence and Promoting Equity

Hayden E. Klein
UnitedHealthcare's oncology payment mode initially involved a pay-for-performance program based on pathways adherence, and will be transitioning in 2024 to a broader system with graded quartiles to incentivize greater participation and pathway adherence.
Samyukta Mullangi, MD, MBA | Image credit: X
January 22nd 2024

Dr Samyukta Mullangi Talks Cost Reductions, Scalability of Thyme Care's Navigation Program

Hayden E. Klein
The Thyme Care virtual navigation program demonstrated a $594 reduction in total costs per member per month for navigated cancer patients compared with a control group, emphasizing the scalability of the independent virtual navigation model across various contracts, with opportunities to adapt to different populations and needs in the evolving landscape of value-based care arrangements.
<1
...
789101112131415
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo